<div id="readability-page-1"><div><div> Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The genomics in cancer care market is on a massive tear, projected to hit $69.16 billion by 2032 as doctors ditch one-size-fits-all treatments for high-tech tumor profiling[1]. Fueling this fire, the cancer biomarker market is expected to reach $62.49 billion by 2033 as AI-driven diagnostics finally take over the clinic[2]. This high-stakes rotation into scalable and proprietary precision platforms fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ: ONCY), BriaCell Therapeutics (NASDAQ: BCTX) (TSX: BCT), Perspective Therapeutics (NYSE-A: CATX), Acrivon Therapeutics (NASDAQ: ACRV), and Greenwich LifeSciences (NASDAQ: GLSI). The broader precision medicine sector is projected to moonshot from $119 billion to a staggering $537 billion by 2035 as Big Pharma pivots toward ultra-efficient registrational trials[3]. A game-changing FDA proposal to reclassify companion diagnostics is now fast-tracking regulatory pathways, positioning 2026 as the year where diagnostic-therapeutic pairings drive both approval speed and massive commercial value[4]. Oncolytics Biotech Inc. (NASDAQ: ONCY) is strengthening its operational and statistical leadership as it advances pelareorep toward multiple registration-directed programs in gastrointestinal cancers. The company recently announced the appointments of John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, bringing deep expertise in late-stage oncology trial execution and regulatory strategy. McAdory joins from CG Oncology, where he served as Vice President of Clinical Operations, leading late-stage development programs for oncolytic virus therapies. Wu arrives from Morphic Therapeutics, where he headed Biostatistics through the company's acquisition by Eli Lilly, and previously led statistical strategy for multiple Phase 3 oncology programs at Takeda. Both executives bring direct experience navigating complex registration trials and global regulatory interactions. &#34;John's background running complex, late-stage oncology trials makes him exceptionally well-suited to lead Oncolytics' next phase of execution,&#34; said Jared Kelly, CEO of Oncolytics Biotech. &#34;As we progress toward pivotal and registration-enabling studies in anal, pancreatic, and colorectal cancers, his experience will be critical to ensuring disciplined execution, speed, and regulatory alignment.&#34; These appointments complete a transformative executive team buildout following Kelly's promotion to CEO last year and the addition of Chief Business Officer Andrew Aromando. They were both crucial contributors to Ambrx Biopharma's $2 billion acquisition by Johnson &amp; Johnson. Oncolytics also recently expanded its Scientific Advisory Board with globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, positioning the company for accelerated clinical development across multiple indications. The strategic focus is advancing pelareorep toward potential accelerated approval in anal cancer after reporting third-line data that achieved a 29% objective response rate—nearly tripling historical benchmarks in a setting with no FDA-approved treatment options. The median duration of response reached approximately 17 months. Second-line or later results were equally compelling, with pelareorep achieving a 30% response rate, more than doubling the 13.8% benchmark for the only FDA-approved immunotherapy in this setting, with a median duration of response of 15.5 months compared to 9.5 months for standard care. Oncolytics has also secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, positioning it to launch the only immunotherapy registration trial currently planned for this disease. CONTINUED… Read this and more news for Oncolytics Biotech at: https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/ In other recent industry developments and happenings in the market include: BriaCell Therapeutics (NASDAQ: BCTX) (TSX: BCT) reported sustained 11-month complete resolution of a lung metastasis in a patient with metastatic breast cancer treated with Bria-OTS, the company's personalized off-the-shelf immunotherapy. The 78-year-old patient with HR-positive, HER2-negative advanced disease and multiple prior treatment failures achieved 100% resolution of lung metastasis following four doses of Bria-OTS single-agent therapy. &#34;The sustained clinical response observed in this late-stage MBC patient, who had previously progressed through multiple prior treatments is remarkable,&#34; said Neal S. Chawla MD, Director at the Sarcoma Oncology Center and Principal Investigator for the Bria-OTS study. &#34;We are excited to further evaluate Bria-OTS in combination with an immune checkpoint inhibitor in metastatic breast cancer.&#34; The complete response was initially observed at 2 months and subsequently confirmed at 4, 6, and 11 months. The patient received 17 cycles of Bria-OTS and completed 12 months of the study without treatment-limiting toxicities. BriaCell has completed the Phase 1 dose escalation portion of the study and initiated the Phase 2a portion evaluating Bria-OTS in combination with an immune checkpoint inhibitor. Perspective Therapeutics (NYSE-A: CATX) presented updated interim data of [212Pb] VMT-α-NET in its ongoing Phase 1/2a clinical trial, demonstrating durable disease control and deepening tumor response. The SSTR2-targeted radiopharmaceutical achieved objective responses in 39% of patients in Cohort 2, regardless of SSTR2 expression profile, including eight confirmed responders and one patient with an initial objective response pending confirmation. &#34;With longer follow-up and a growing body of clinical experience, we continue to see evidence of sustained and deepening anti-tumor activity for VMT-α-NET at the dose level evaluated in Cohort 2, while the favorable tolerability profile is maintained, possibly even at a higher dose,&#34; said Vikas Prasad, MD, Professor of Radiology at Siteman Cancer Center, Washington University School of Medicine. &#34;These data further support continued dose optimization, and I look forward to discussing the evolving results with the gastrointestinal oncology community as this study progresses.&#34; Across 56 patients who received at least one treatment, [212Pb] VMT-α-NET continued to be well-tolerated with no dose-limiting toxicities, treatment-related discontinuations, serious renal complications, or clinically significant treatment-related myelosuppression. Cohort 3 dose-limiting toxicity assessment was completed as planned and cleared to treat more patients. Perspective Therapeutics expects to engage with regulatory agencies during 2026 on proceeding into a registrational trial. Acrivon Therapeutics (NASDAQ: ACRV) announced positive data from its ACR-368 Phase 2b trial in endometrial cancer, showing a 39% overall response rate in OncoSignature-positive patients with a 67% confirmed response rate in BM-positive patients with serous subtype. The company has expanded the trial into the European Union across more than 20 sites in Germany, Italy, France and Spain, with Arm 3 enrolling up to 90 patients with serous subtype who have received two or fewer prior lines of therapy. &#34;We are particularly excited by the observation from our ongoing ACR-368 Phase 2 trial that subjects with serous endometrial cancer with up to two prior lines of therapy are showing over 50% confirmed response rate,&#34; said Peter Blume-Jensen, M.D., Ph.D., CEO, President and co-founder of Acrivon Therapeutics. The company has also submitted a Phase 3 confirmatory protocol to the FDA for ACR-368 plus anti-PD-1 therapy in frontline endometrial cancer patients based on preclinical data showing strong synergy. Acrivon expects to complete Arm 3 enrollment in the fourth quarter of 2026, with global trial readiness for the Phase 3 study anticipated mid-2026. Greenwich LifeSciences (NASDAQ: GLSI) provided updates on FLAMINGO-01 and corporate strategy, including fully enrolling the 250-patient non-HLA-A*02 arm, where all patients received GLSI-100. Preliminary analysis shows an approximately 80% reduction in recurrence rate after the Primary Immunization Series, trending similarly to Phase IIb trial results, where breast cancer recurrences were reduced up to 80% in HLA-A02 patients. &#34;We are looking forward to continuing our financing strategy and implementing the planned Phase III trial derisking modifications, pending regulatory approvals,&#34; said Snehal Patel, CEO of Greenwich LifeSciences. &#34;The discussions with clinicians at SABCS 2025 were encouraging, as the study has become more widely recognized by the breast cancer community, leading to patient and investigator driven interest to expand FLAMINGO-01 into the United Kingdom and Canada. The potential for GLSI-100 to save lives by preventing metastatic breast cancer recurrences and thus reduce overall healthcare costs was also highlighted at the Noble conference.&#34; The study has transitioned from investigator-driven to patient-driven interest, with wait lists forming at certain sites. More than 1,000 patients have been screened with approximately 140 sites actively enrolling, and Greenwich LifeSciences is in discussions with leading clinical sites in the United Kingdom and Canada regarding joining the study. Source: https://usanewsgroup.com/2024/09/21/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/ CONTACT: Baystreet.ca [email protected] (250) 999-4849 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Baystreet.ca is a wholly-owned subsidiary of Baystreet.ca Media Corp. (“BAY”) BAY has been not been paid a fee for Oncolytics Biotech Inc. advertising and/or digital media, but the owner(s) of BAY also own Market IQ Media Group, Inc., which has been paid a fee from the company directly. There may be 3rd parties who may have shares Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Oncolytics Biotech Inc. which were purchased in the open market. BAY and all of it’s respective employees, owners and affiliates reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by BAY has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. SOURCES CITED: 1. https://www.globenewswire.com/news-release/2026/01/05/3212639/0/en/Genomics-in-Cancer-Care-Market-Size-to-Hit-USD-69-16-Billion-by-2032-Growing-at-a-CAGR-of-16-04-SNS-Insider.html 2. https://www.openpr.com/news/4337223/cancer-biomarker-market-to-reach-us-62-49-billion-by-2033 3. https://www.globenewswire.com/news-release/2025/12/22/3209349/0/en/Global-Precision-Medicine-Market-Growth-Accelerates-at-16-26-CAGR-Through-2035-Expands-Rapidly-as-AI-Genomic-Testing-and-Targeted-Therapies-Gain-Momentum.html 4. https://www.bioanalysis-zone.com/fda-proposes-shake-up-for-core-oncology-companion-diagnostic-classification/</div></div></div>

CATX

ONCY

The genomics in cancer care market is projected to reach $69.16 billion by 2032, driven by advancements in tumor profiling and AI diagnostics. Oncolytics Biotech Inc. is enhancing its leadership team to advance its cancer treatment, pelareorep, with promising trial results. The broader precision medicine sector is expected to grow from $119 billion to $537 billion by 2035. Other companies like BriaCell Therapeutics and Perspective Therapeutics are also making significant strides in cancer therapies, showcasing promising clinical results and innovative approaches in oncology.

The $69B Precision Pivot: Why Biomarker Platforms are Igniting a New Oncology Gold Rush